Literature DB >> 2700187

Hyperlipidaemia in uraemic patients under chronic haemodialysis. Correlation with serum lipoprotein lipase and insulin levels.

M A Sobh1, S A Shamaa, A M el-Gayar, M M el-Sharabacy.   

Abstract

Hyperlipidaemia is implicated in vascular complications of uraemic patients on haemodialysis. In this work serum lipids, serum lipoprotein lipase (LPL) and insulin levels were measured in 45 chronic uraemic patients on haemodialysis and 44 healthy volunteers. A significant rise in total lipids (TL), cholesterol and triglycerides (TG) was detected in the haemodialysis patients, but no changes were found in either serum phospholipids or high density lipoprotein cholesterol (HDL-chol.). The rise in TL, TG and cholesterol was positively correlated with the duration of dialysis but not with age or sex. On the other hand, a significant rise was also observed in serum LPL and insulin levels but with no correlation between any of them and the lipid levels. From this study it may be apparent that other factors rather than LPL abnormalities may be implicated in hyperlipidaemia in uraemic patients under haemodialysis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2700187     DOI: 10.1007/BF02559625

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  13 in total

1.  Serum lipase activity in chronic renal failure.

Authors:  H Sommer; H Kasper; T Fösel
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1975-08

2.  A new enzymatic method for determination of serum choline-containing phospholipids.

Authors:  M Takayama; S Itoh; T Nagasaki; I Tanimizu
Journal:  Clin Chim Acta       Date:  1977-08-15       Impact factor: 3.786

3.  Defective triglyceride removal in lipemia associated with peritoneal dialysis and haemodialysis.

Authors:  D C Cattran; S S Fenton; D R Wilson; G Steiner
Journal:  Ann Intern Med       Date:  1976-07       Impact factor: 25.391

4.  Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study.

Authors:  L A Carlson; L E Böttiger
Journal:  Lancet       Date:  1972-04-22       Impact factor: 79.321

5.  Hypertriglyceridemia. A metabolic consequence of chronic renal failure.

Authors:  J D Bagdade; D Porte; E L Bierman
Journal:  N Engl J Med       Date:  1968-07-25       Impact factor: 91.245

6.  A colorimetric method for determination of total serum lipids based on the sulfo-phospho-vanillin reaction.

Authors:  C S Frings; R T Dunn
Journal:  Am J Clin Pathol       Date:  1970-01       Impact factor: 2.493

7.  Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.

Authors:  W B Kannel; W P Castelli; T Gordon; P M McNamara
Journal:  Ann Intern Med       Date:  1971-01       Impact factor: 25.391

8.  Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease.

Authors:  G J Miller; N E Miller
Journal:  Lancet       Date:  1975-01-04       Impact factor: 79.321

9.  Cholesterol determination in high-density lipoproteins separated by three different methods.

Authors:  M F Lopes-Virella; P Stone; S Ellis; J A Colwell
Journal:  Clin Chem       Date:  1977-05       Impact factor: 8.327

10.  Insulin resistance in uremia. Characterization of lipid metabolism in freshly isolated and primary cultures of hepatocytes from chronic uremic rats.

Authors:  J F Caro; S Lanza-Jacoby
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

View more
  2 in total

1.  Long term hemodialysis aggravates lipolytic activity reduction and very low density, low density lipoproteins composition in chronic renal failure patients.

Authors:  Khedidja Mekki; Josiane Prost; Mustapha Remaoun; Jacques Belleville; Malika Bouchenak
Journal:  BMC Cardiovasc Disord       Date:  2009-08-26       Impact factor: 2.298

2.  Coronary risk factors in maintenance hemodialysis patients: Who is the culprit - hemodialysis or chronic renal failure?

Authors:  Kapil Gupta; Rajiv Mahajan
Journal:  Int J Appl Basic Med Res       Date:  2011-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.